Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients

NPJ Prim Care Respir Med. 2020 Oct 20;30(1):47. doi: 10.1038/s41533-020-00207-7.

Abstract

This study reports the association of ICS use and the risk of type 2 diabetes mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary care settings. A total of 7078 patients with COPD were included in this analysis and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of ICS especially at a high dose in patients with COPD was related to an increased risk of T2DM.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / adverse effects*
  • Adrenal Cortex Hormones / therapeutic use
  • Aged
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / adverse effects*
  • Bronchodilator Agents / therapeutic use
  • Diabetes Mellitus, Type 2 / chemically induced*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Female
  • Humans
  • Incidence
  • Male
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Risk Factors
  • Sweden / epidemiology

Substances

  • Adrenal Cortex Hormones
  • Bronchodilator Agents